Compare AbbVie Inc (ABBV) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? AbbVie Inc trades at $253.88 (market cap $449.91B), while Invesco S&P 500 Low Volatility ETF trades at $76.21. The key difference: AbbVie Inc pays a 2.72% dividend while Invesco S&P 500 Low Volatility ETF pays none. Which is the better fit depends on your goals.
| ABBV | SPLV | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $77.45 |
52-Week Low | $184.85 | $70.30 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
SPLV trades at $76.17, down 0.73% today, maintaining a bullish technical outlook with strong moving average support. The ETF focuses on low-volatility S&P 500 stocks, offering defensive exposure during market uncertainty. Recent news highlights its role in portfolio diversification amid tech sector volatility, with institutional investors showing mixed positioning.
The outlook remains positive for risk-averse investors seeking stable equity exposure. Key risks include potential underperformance during strong bull markets and concentration in defensive sectors. Analyst sentiment is generally favorable for defensive portfolio allocation, though specific financial metrics for the ETF are not publicly detailed like individual stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
